【24h】

Practical fluorimetric assay for the detection of anticancer drug SN-38 in human plasma

机译:用于检测人血浆中抗癌药物Sn-38的实用荧光测定

获取原文
获取原文并翻译 | 示例
           

摘要

The implementation of therapeutic drug monitoring in the routine clinical practice in oncology is mainly limited by the lack of therapeutic indexes for the majority of the anticancer drugs, and by the absence of suitable analytical tools, which can accurately quantify in real time the concentration of the administered drugs and their relevant metabolites in biological fluids. In this work, a simple and efficient fluorimetric determination of SN-38, the active metabolite of the anticancer drug irinotecan, was developed and applied to human plasma samples. The intrinsic fluorescence of SN-38 allowed its quantification in the range 10–500?ng?mL?1with a LOQ of 5.0?ng?mL?1and a LOD of 1.5?ng?mL?1. Low interferences due to main metabolites of irinotecan and comedications, commonly associated with administration of irinotecan, were observed. A validation study, according to FDA and EMA guidelines for bioanalytical method validation, was carried out and, finally, blind samples were analyzed in parallel with a HPLC-MS method obtaining an excellent agreement between the two techniques.
机译:在肿瘤学常规临床实践中实施治疗药物监测主要受到大多数抗癌药物缺乏治疗指标的限制,并且由于没有合适的分析工具,可以在实时准确地量化的在生物液中施用药物及其相关代谢物。在这项工作中,开发了一种简单富含荧光荧光测定Sn-38,抗癌药物伊替康的活性代谢物,并应用于人血浆样品。 SN-38的内在荧光允许其定量在10-500°的范围内,其量为5.0≤ml≤1μm≤1μl≤1μl≤10Ω·毫升α1。观察到由于伊替康的主要代谢产物和与伊替康省施用常见的伊替替康和可见性的低干扰。根据FDA和EMA生物分析方法验证的指南进行验证研究,最后,与HPLC-MS方法并行分析盲目样品,从而在两种技术之间获得了很好的一致性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号